Posted by Michael Wonder on 01 Nov 2024
ICER publishes evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
31 October 2024 - Current evidence suggests that tabelecleucel provides a substantial net health benefit when compared to usual care; treatment would achieve common thresholds for cost effectiveness if priced between $143,900 - $273,700 per treatment cycle —
The ICER today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of tabelecleucel (Pierre Fabre) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease.
